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Background: Radiation induced optic neuropathy (RION) is a rare but severe consequence of radiation therapy
that is associated with adjuvant chemotherapy, specifically therapy with vincristine or nitrosoureas. However, there
is very little evidence regarding the occurrence of RION after concomitant radiochemotherapy with temozolomide.
Case Presentation: The case of a 63 year old woman with glioblastoma multiforme and concomitant
radiochemotherapy with temozolomide is described. Due to a slight depressive episode the patient also took
hypericum perforatum. Five months after cessation of fractionated radiation and adjuvant chemotherapy with
temozolomide (cumulative dose of 11040 mg) the patient developed bilateral amaurosis due to RION. Tumor
regrowth was excluded by magnetic resonance imaging. After the application of gadolinium a pathognomonic
contrast enhancement of both prechiasmatic optic nerves could be observed.
Conclusions: In this patient, the occurrence of RION may have been the result of radiosensitization by
temozolomide, which could have been strengthened by hypericin. Consequently, physicians should avoid a
concomitant application of hypericum perforatum and radiochemotherapy.
Background
Radiation-induced optic neuropathy (RION) is a compli-
cation of radiotherapy to the anterior visual pathway. It
can occur from 3 months to more than 8 years after
radiation exposure [1]. Latency to the onset of symptoms
is related to the radiation dose: A total cumulative dose
of fractionated radiation above 63 Gy is associated with
an increasing risk inducing an optic neuropathy [2].
Additional predisposing risk factors are age and diabetes
mellitus [2]. In addition, a pre-existing compression to
the optic nerves and the chiasm may predispose these
structures to injury by radiotherapy [3]. RION has been
described mainly in patients with tumors of nasopharynx,
paranasal sinuses, nasal cavity, pituitary adenoma, cranio-
pharyngioma, skull base and orbita [2,4,5]. Since some
chemotherapeutic agents, namely vincristine, nitrosour-
eas and cisplatin [6,7] are associated with optic nerve
toxicity and/or can serve as radiosensitizers [8], those
patients receiving adjuvant chemotherapy have an espe-
cially high risk of developing RION.
To our knowledge, there is only one glioblastoma
patient in literature who developed a left-sided optic neu-
ropathy after concomitant radiochemotherapy with
temozolomide and bevacizumab [9]. However, since
there was a damage of the optic pathway as a secondary
consequence of tumor growth a relation to the applied
radiochemotherapy remained doubtful.
Therefore, although there is substantial literature con-
cerned with RION, a bilateral radiation induced optic
neuropathy has never been described in a patient with
glioblastoma multiforme who was concomitantly treated
only with temozolomide. Here, we present such a case. * Correspondence: stefanie.schreiber@med.ovgu.de
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A 63 year old woman was presented with severe head-
ache and psychomotor slowing that had recurred for
some weeks. Her medical history revealed a mild arterial
hypertension and a slight depressive episode with sleep
disturbances. To treat the depressive episode the patient
self-medicated with hypericin (St. John’s wort, hyperi-
cum perforatum) with a dosage of 900 mg per day,
probably for several months before she was transferred
to our department. No vision disorders were found.
MRI revealed a contrast-enhanced 4.6 × 3.8 × 3.1 cm
lesion in her right temporal lobe, with no observable
compression of the optic nerves or optic chiasm (Figure
1A, B). A glioblastoma multiforme was suspected and
confirmed histologically after open surgery with a resec-
tion of more than 90% of tumor tissue. After surgery,
concurrent photon radiation (involved field, two co-axial
isocentric fields, fractionated, once daily; cumulative
dose 60 Gy, fraction size 2 Gy) and chemotherapy with
temozolomide (75 mg/m
2 body surface, total dose of
5040 mg) were implemented for a duration of 6 weeks.
Target volumes and organs at risk, such as chiasm, were
delineated on MRI (Figure 2A). The maximum doses to
the optic nerves and chiasm were obtained from dose-
volume histograms (DVHs) (Figure 2B). The maximal
cumulative radiation doseo f5 6G y( m a x i m a ls i n g l e
dose 1.8 Gy) was delivered to less than 20% of the optic
chiasm. Residual parts of the optic decussation were
irradiated with a median cumulative dose of 46 Gy.
Maximal cumulative dose to the right and left optic
nerves were 57 Gy and 24 Gy. After starting radiation,
the patient described a headache that also affected the
right eye, with symptoms occurring daily and increasing
during the course of the day. Karnofsky performance
status [10] remained stable at about 70%. Six weeks
after completion of the initial course of treatment
(concomitant radiochemotherapy), 4 additional cycles of
chemotherapy with temozolomide (150-200 mg/m
2 body
surface, total dose of 6000 mg) were performed.
A progressive visual loss due to bilateral amaurosis
occurred 5 months after cessation of radiation. This
symptom was accompanied by visual hallucinations.
Ophthalmological examination revealed bilateral
amaurotic fixed pupils and a slightly pale optic disc.
Vision loss from other causes, such as optic nerve or
chiasm compression by tumor progression (MRI [Figure
3] and single photon emission computed tomography
[SPECT] were performed), retinal disorders, cataract, or
bilateral giant cell arteritis, were carefully excluded.
Detected visual acuity was 0/100 in both eyes. No visual
evoked potentials could be generated by either monocu-
lar or binocular excitation with flashing lights and con-
trast inversions. Except for a slight elevation of protein
concentration, there were no indications of infectious
disease or other pathological findings in the patient’s
cerebrospinal fluid. Four months after RION appeared
the visual loss persisted; Karnofsky performance status
declined to 40%.
Conclusions
Here we present the first report of a patient with glioblas-
toma multiforme developing a bilateral RION about
Figure 1 Images before surgery and radiochemotherapy. On T2 (Figure 1A) and gadolinium enhanced T1 (Figure 1B) weighted magnetic
resonance imaging in histologically confirmed glioblastoma multiforme of the right temporal lobe can be seen. Note that there is no
compression/infiltration of the adjacent optic nerve, the chiasm or the right internal carotid artery.
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apy with temozolomide. An intrinsic mass in the optic
nerves and/or chiasm was excluded by MRI, as was a
compression of those structures by a possible recurrence
of the tumor. In addition, a contrast enhancement
of both prechiasmatic optic nerves could be observed
after gadolinium application (Figure 3). Gadolinium
enhancement of the optic nerve anywhere from its
extraocular-intraorbital part to the optic chiasm seems to
be a characteristic finding of RION in MR-Imaging, since
it has been described by several groups as the most
common type of radiation induced optic neuropathy
[11,12]. Accumulation of the contrast medium could be
explained by a disruption of the blood-brain-barrier [5]
t h a tm a yp l a yar o l ei nt h ep a t h o g e n e s i so fR I O N ,
which is associated with delayed radionecrosis, damage
and depletion of vascular endothelium and ischemic
demyelination [13].
Concerning fractionated once-daily radiation, the 10-
year rates for freedom from optic neuropathy are respec-
tively about 96% and 78% after the application of a total
optic nerve dose of ≤ 63 Gy and a fraction dose of ≤1.8
Gy [2]. Our patient received a total cumulative dose of 60
Gy with a fraction size of 2 Gy and a maximal chiasm and
optic nerve dose of 56 Gy and 57 Gy, with less than 20%
of the optic chiasm and nerves subjected to that total
cumulative dose (Figure 2B). Since prescriptive limits for
radiation dose were maintained, other causes that could
have aggravated the radiation effect should be taken into
consideration. At time of radiation the patient’sa g ew a s
older than 60 years, which has been depicted as signifi-
cant covariate for vision loss. The patient did not suffer
from diabetes, the second significant covariate for RION
[4]. Female gender and arterial hypertension have not
been found to be significant risk factors for radiation-
induced optic neuropathy [4].
In addition, the possible effects of the patients’ concomi-
tant therapy with temozolomide and hypericin should be
addressed. Interestingly, at least tumor cells undergo apop-
tosis when treated with photodynamic therapy sensitized
with hypericin [14]. This process has been described as
being associated with a cleavage of poly-[ADP-ribose]-
polymerase (PARP) [15], participating in cellular recovery
from DNA damage [16]. An inhibition or cleavage of
Figure 2 Target volume and dose-volume histogram. Figure 2A Magnetic resonance imaging after open surgery with isodose lines from 10 to
110%. Target volume is marked in red, chiasm in green and brainstem in blue. Figure 2B Dose-volume histogram (DVH) of the radiation shows the
dose given to the percentage of OAR (organ at risk) volume, i.e. less than 20% of the chiasm was irradiated with 56 Gy within 6 weeks.
Figure 3 Images 5 months after cessation of radiation.T 1
weighted gadolinium enhanced magnetic resonance imaging
revealing subtle contrast enhancement of the left and right
prechiasmatic optic nerve 5 months after cessation of radiation
when bilateral amaurosis occurred. Note that there is no infiltration
of the chiasm by tumor recurrence.
Schreiber et al. BMC Cancer 2010, 10:520
http://www.biomedcentral.com/1471-2407/10/520
Page 3 of 5PARP might enhance the cytotoxicity of temozolomide
[17] and might lead to radiosensitization [18] at least in
the case of tumorcells. To what extent these processes
also take place in the healthy tissue of the optic nerves and
the chiasm has not been determined. However, since
temozolomide is known to induce at least unilateral visual
loss (summary of product characteristics by the producer
of temozolomide, Essex Chemie AG, Luzern, Switzerland),
produces visual loss when combined with thalidomide
[19], serves as a “radiosensitizer” [8], and distributes in
normal brain tissue [20], a damaging effect of temozolo-
mide on the optic nerves/chiasm (possibly strengthened
by hypericin) is conceivable.
In addition hypericin has inhibitory effects on protein
kinase C (PKC) [21], which might be associated with the
activation of caspases, required for radiation mediated
apoptosis [21]. Hence, several preclinical studies have
demonstrated that the inhibition of PKC enhances the
effect of ionization radiation [22,23]. On the other hand,
tissue warming caused by radiation, accelerates apopto-
tic effects of hypericin [24]. Thus, an additional interplay
between radiation and hypericin, associated with apop-
tosis of endothelial cells and oligodendrocytes [25], may
have occurred.
Since many patients with high-grade glioma suffer
from depression, fatigue and sleep disorders [26] and
since mild depressive disorders are an indication for the
use of St. John’s wort [27], many patients with glioblas-
toma multiforme may take hypericin. In view of the case
of bilateral RION we report, and the aforementioned
possible connection between St. John’s wort and both
temozolomide and the effects of radiation, physicians
should be careful about administering hypericin simulta-
neously with radiochemotherapy.
Consent
Written informed consent could not be obtained from
the patient for publication of this case report and any
accompanying images because the patient has died. The
patient’s son has consented to publishing the data.
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